Potential applications of nanoparticles in cancer immunotherapy

Jia, Yimei; Omri, Abdelwahab; Krishnan, Lakshmi; McCluskie, Michael J.

doi:10.1080/21645515.2016.1245251

Cited by 40 publications

(28 citation statements)

References 125 publications

(128 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some FDA-approved immune checkpoint agents are ipilimumab against CTLA-4, and pembrolizumab and nivolumab against PD-1. Lipid-based NPs are generally used to transport these materials to the target site [ 161 ]. A study showed that R848-loaded β —cyclodextrin NPs can efficiently be delivered to tumour-associated macrophages in vivo to macrophages to acquire an antitumourigenic M1-like phenotype.…”

Section: Cancer Therapymentioning

confidence: 99%

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

2020

View full text Add to dashboard Cite

Nanomaterials, such as nanoparticles, nanorods, nanosphere, nanoshells, and nanostars, are very commonly used in biomedical imaging and cancer therapy. They make excellent drug carriers, imaging contrast agents, photothermal agents, photoacoustic agents, and radiation dose enhancers, among other applications. Recent advances in nanotechnology have led to the use of nanomaterials in many areas of functional imaging, cancer therapy, and synergistic combinational platforms. This review will systematically explore various applications of nanomaterials in biomedical imaging and cancer therapy. The medical imaging modalities include magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computerized tomography, optical imaging, ultrasound, and photoacoustic imaging. Various cancer therapeutic methods will also be included, including photothermal therapy, photodynamic therapy, chemotherapy, and immunotherapy. This review also covers theranostics, which use the same agent in diagnosis and therapy. This includes recent advances in multimodality imaging, image-guided therapy, and combination therapy. We found that the continuous advances of synthesis and design of novel nanomaterials will enhance the future development of medical imaging and cancer therapy. However, more resources should be available to examine side effects and cell toxicity when using nanomaterials in humans.

show abstract

Section: Cancer Therapymentioning

confidence: 99%

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

2020

View full text Add to dashboard Cite

show abstract

“…Consequently, immunoproteasome-deficient BMDCs showed impaired CP ability in vitro, as well as in vivo, in a mouse model [82]. The cytoplasmic delivery of exogenous proteins enhanced CP efficiency in a murine model [89]. Expression of PLC was higher in splenic cDC1s than in splenic cDC2s [44], and cDC1s were responsible for both cross-priming [44] and for cross-tolerance [90].…”

Section: Two Pathways For Cross-presentation (Cp)mentioning

confidence: 99%

“…The cytoplasmic delivery of exogenous proteins largely enhances CP efficiency [89], indicating that the retro-transport of internalized protein from endocytic compartments to the cytosol is one of the rate-limiting processes for an efficient CP. The intracellular transport pathways of extracellular proteins are different among DC subsets, such as cDC1s, moDCs, or BMDCs.…”

Section: The Non-classical Endosomementioning

confidence: 99%

“…Together, these results strongly suggest that peptide loading in CP is carried out by newly synthesized MHC I in the ER or in the non-classical endocytic compartments, which also supports the notion that the effective transport of extracellular proteins into the non-classical endocytic compartments is one of the most important requirements for DC vaccination. While the source of MHC I has not been precisely determined yet, the results of cytoplasmic delivery of exogenous proteins [89] indicate that the amounts of MHC I in DCs are sufficient, and that loading onto MHC I is not a rate-determining step in CP.…”

Section: Peptide Loading Onto Mhc Imentioning

confidence: 99%

See 1 more Smart Citation

Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review

2020

View full text Add to dashboard Cite

While the success of dendritic cell (DC) vaccination largely depends on cross-presentation (CP) efficiency, the precise molecular mechanism of CP is not yet characterized. Recent research revealed that endoplasmic reticulum (ER)-associated degradation (ERAD), which was first identified as part of the protein quality control system in the ER, plays a pivotal role in the processing of extracellular proteins in CP. The discovery of ERAD-dependent processing strongly suggests that the properties of extracellular antigens are one of the keys to effective DC vaccination, in addition to DC subsets and the maturation of these cells. In this review, we address recent advances in CP, focusing on the molecular mechanisms of the ERAD-dependent processing of extracellular proteins. As ERAD itself and the ERAD-dependent processing in CP share cellular machinery, enhancing the recognition of extracellular proteins, such as the ERAD substrate, by ex vivo methods may serve to improve the efficacy of DC vaccination.

show abstract

“…These cationic lipid-assisted PEG-PLAbased NPs efficiently delivered siRNA into T cell in vitro and significantly increased the percentage of anti-tumour CD8 + T cells, while also decreasing the ratio of CD4 + FOXP3 + T reg among tumour infiltrating lymphocytes (TILs), resulting in the inhibition of tumour growth and prolonged survival time. 42,43 Finally, tumours can develop phenotypes that are less immunogenic.…”

Section: How Could Nps Be Used As a Booster For The Abscopal Effect?mentioning

confidence: 99%

Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies

Morales-Orue¹,

Chicas-Sett²,

Lara³

2019

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

Over the last decade, immunotherapy has emerged as a hopeful alternative in cancer therapy. Different drugs are used to stimulate the immune system and block negative immune regulatory pathways, known as "immune checkpoint inhibitors (ICI)". Although clinical studies have reported efficacy and safety with the use of ICI, only a small group of patients have obtained a clinical benefit. Because of this, immunomodulation based on immunogenic cell death produced by radiotherapy (RT) has been well positioned as an alternative to increase the clinical effect on the primary neoplasm, but also in distant tumours, a phenomenon known as the "abscopal effect". Early clinical outcomes with RT-ICI combination are promising, but the rate of abscopal responses remains low. These developments have opened a path to evaluate the use of nanotechnology as antigen-capturing nanoparticles (AC-NPs) for improving clinical outcomes in metastatic disease treated with RT-ICI. In this review, we aim to highlight the basic characteristics of nanoparticles and its application in oncology, focusing on their potential to enhance abscopal responses.

show abstract

Potential applications of nanoparticles in cancer immunotherapy

Cited by 40 publications

References 125 publications

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review

Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies

Contact Info

Product

Resources

About